Sangamo Therapeutics Inc. has transferred SB-525 to Pfizer Inc., its partner in developing the gene therapy for treating the bleeding disorder hemophilia A.
As per their agreement, Richmond, Calif.-based Sangamo handled the early- and mid-stage trials of the drug while Pfizer will take charge of the drug's late-stage trial, expected in 2020.
SB-525 is an investigational gene therapy for severe hemophilia A, a genetic bleeding disorder in which the blood does not clot normally due to the absence or low levels of factor VIII, a protein needed to form blood clots.
Sangamo received $25 million as a milestone payment from New York-based pharmaceutical giant Pfizer.
Sangamo is eligible for total milestone payments of up to $300 million for developing and commercializing SB-525 and tiered royalties from the low teens up to 20% of net yearly sales of SB-525. The company will also receive up to $175 million for additional Hemophilia A gene therapies it co-develops with Pfizer.
The U.S. Food and Drug Administration tagged Sangamo-Pfizer's SB-525 as a regenerative medicine advanced therapy in July and gave it orphan-drug and fast-track designations in 2017.
The gene therapy has also received an orphan medicinal product status from the European Medicines Agency.